Drug Patents owned by Salix Pharms

1. List of Moviprep drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169381 SALIX PHARMS Colon cleansing compositions and methods
Sep, 2024

(1 year, 6 months from now)

US7658914 SALIX PHARMS Colon cleansing compositions
Sep, 2024

(1 year, 6 months from now)

How can I launch a generic of MOVIPREP before it's patent expiration?
More Information on Dosage

2. List of Osmoprep drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7687075 SALIX PHARMS Colonic purgative composition with soluble binding agent
Jun, 2028

(5 years from now)

How can I launch a generic of OSMOPREP before it's patent expiration?
More Information on Dosage

3. List of Relistor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376584 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(1 year, 2 months from now)

US9669096 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(1 year, 2 months from now)

US8552025 SALIX PHARMS Stable methylnaltrexone preparation
Apr, 2024

(1 year, 2 months from now)

US8822490 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9492445 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9180125 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US8420663 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US8247425 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Dec, 2030

(7 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Market Authorisation Date: 24 April, 2008

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of RELISTOR before it's patent expiration?
More Information on Dosage

4. List of Xifaxan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7045620 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
Jun, 2024

(1 year, 4 months from now)

US8158781 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(1 year, 4 months from now)

US8835452 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(1 year, 4 months from now)

US7612199 SALIX PHARMS Polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(1 year, 4 months from now)

US7902206 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(1 year, 4 months from now)

US7906542 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2025

(2 years from now)

US8741904 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Feb, 2026

(3 years from now)

US8193196 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Sep, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8853231 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(1 year, 4 months from now)

US8158644 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(1 year, 4 months from now)

US7915275 SALIX PHARMS Use of polymorphic forms of rifaximin for medical preparations
Feb, 2025

(2 years from now)

US10703763 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Feb, 2026

(3 years from now)

US8518949 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Feb, 2026

(3 years from now)

US9271968 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Feb, 2026

(3 years from now)

US10765667 SALIX PHARMS Methods for treating irritable bowel syndrome (IBS)
Feb, 2029

(6 years from now)

US10456384 SALIX PHARMS Methods for treating irritable bowel syndrome (IBS)
Feb, 2029

(6 years from now)

US8309569 SALIX PHARMS Methods for treating diarrhea-associated irritable bowel syndrome
Jul, 2029

(6 years from now)

US10709694 SALIX PHARMS Methods of treating hepatic encephalopathy
Jul, 2029

(6 years from now)

US7928115 SALIX PHARMS Methods of treating travelers diarrhea and hepatic encephalopathy
Jul, 2029

(6 years from now)

US9421195 SALIX PHARMS Methods of treating hepatic encephalopathy
Jul, 2029

(6 years from now)

US8946252 SALIX PHARMS Methods of treating traveler's diarrhea and hepatic encephalopathy
Jul, 2029

(6 years from now)

US10335397 SALIX PHARMS Methods of treating hepatic encephalopathy
Jul, 2029

(6 years from now)

US9629828 SALIX PHARMS Methods of treating traveler's diarrhea and hepatic encephalopathy
Jul, 2029

(6 years from now)

US10314828 SALIX PHARMS Methods of treating hepatic encephalopathy
Jul, 2029

(6 years from now)

US8829017 SALIX PHARMS Methods of treating traveler's diarrhea and hepatic encephalopathy
Jul, 2029

(6 years from now)

US8969398 SALIX PHARMS Methods of treating hepatic encephalopathy
Oct, 2029

(6 years from now)

US8642573 SALIX PHARMS Methods of treating hepatic encephalopathy
Oct, 2029

(6 years from now)

Drugs and Companies using RIFAXIMIN ingredient

Market Authorisation Date: 25 May, 2004

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; Treatment of travelers' diarrhea (td) caused by noninvasive strains of escheria coli in adult and pediatric patients 12 years of age and older; Reduction in risk of overt hepatic encephalopathy (he) recurrence in adults; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; Method of treating travelers' diarrhea; Reduction in risk of overt hepatic encephalopathy (he) recurrence; Reduction in risk of overt hepatic encephalopathy (he) in adults; Treatment of patients with hepatic encephalopathy (he); The treatment of patients with travelers' diarrhea (td) or the reduction in risk of overt hepatic encephalopathy (he) recurrence

Dosage: TABLET;ORAL

How can I launch a generic of XIFAXAN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in